ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Lower Frequency of Regulatory T-Cells After Conversion from CNIs or mTORi to Belatacept in a Prospective Matched Controlled Study in Renal Allograft Recipients

M. Dürr, J. Liu, K. Budde.

Nephrology, Charité
Universitätsmedizin Berlin, Berlin, Germany.

Meeting: 2015 American Transplant Congress

Abstract number: D11

Keywords: Co-stimulation, Lymphocytes, Proliferation

Session Information

Session Name: Poster Session D: Costimulation and Signaling in Lymphocytes

Session Type: Poster Session

Date: Tuesday, May 5, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Objective: Regulatory T-cells (Tregs) are considered to play a crucial role in maintaining control of immune response following renal transplantation (Tx). So far, only limited data are available from prospective controlled trials on the time course and frequency of Tregs after conversion from either Calcineurin inhibitors (CNIs) or mammalian target of Rapamycin inhibitors (mTORi) to Belatacept, a co-stimulatory blocker of CD80/86. The aim of this study was to evaluate the influence of belatacept on T-cell subsets with focus on Tregs after withdrawal from CNI or mTORi.

Methods: 20 renal transplant patients (pts) on either CNIs (n=10) or mTORi (n=10), who had intolerability of their maintenance regimen participated in a prospective controlled 12-month trial. Conversion from CNI or mTORi to belatacept was performed in a stepwise manner over a 4-week period. Characterization of T-cell subsets and Treg phenotype was performed at baseline, month (Mo) 1, 3 and 6, respectively. Peripheral blood mononuclear cells were analyzed with multi-color flow cytometry using antibodies against CD3/8/4/25 and CD127. Additionally, we isolated CD4CD25Tregs and co-cultured them with CD4 effector cells (Teffs) to evaluate their suppressive capacity.

Results: Actually, 15 pts passed interim analysis 6 Mo after conversion to belatacept. At 3 Mo, frequency of CD4+CD25+CD127low Treg decreased in CNI and mTORi withdrawal groups. In addition, Tregs dropped to their minimum 6 Mo after conversion (CNI 2.9%; p=0.003; mTORi 4%; p=0.068, ). Despite reduced Treg numbers after conversion to belatacept, the suppressive function of Tregs was not impaired when Teffs are co-cultured with Tregs 1:1 (CNI-group: BL=33%, Mo3=31%, Mo6=20%; p=0.11)(mTORi-group: BL=27%, Mo3=24%, Mo6=19%; p=0.4).

Conclusion: The present study demonstrated a decrease of Treg frequency after conversion from either CNI or mTORi to belatacept. Despite lower Treg frequencies, suppressive Treg function was not restricted under belatacept therapy. These data may help to better understand the biology of Treg function in context of co-stimulatory blockade.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Dürr M, Liu J, Budde K. Lower Frequency of Regulatory T-Cells After Conversion from CNIs or mTORi to Belatacept in a Prospective Matched Controlled Study in Renal Allograft Recipients [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/lower-frequency-of-regulatory-t-cells-after-conversion-from-cnis-or-mtori-to-belatacept-in-a-prospective-matched-controlled-study-in-renal-allograft-recipients/. Accessed May 11, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences